BRIEF-US priority review for Bayer liver cancer drug regorafenib

* Regorafenib from Bayer granted priority review in USA For

second-line treatment of liver cancer

Source text for Eikon:

Further company coverage:

(Reporting By Georgina Prodhan)

Read more